Author:
Penwell William F.,Shapiro Adam B.,Giacobbe Robert A.,Gu Rong-Fang,Gao Ning,Thresher Jason,McLaughlin Robert E.,Huband Michael D.,DeJonge Boudewijn L. M.,Ehmann David E.,Miller Alita A.
Abstract
ABSTRACTSulbactam is a class A β-lactamase inhibitor with intrinsic whole-cell activity against certain bacterial species, includingAcinetobacter baumannii. The clinical use of sulbactam forA. baumanniiinfections is of interest due to increasing multidrug resistance in this pathogen. However, the molecular drivers of its antibacterial activity and resistance determinants have yet to be precisely defined. Here we show that the antibacterial activities of sulbactam vary widely across contemporaryA. baumanniiclinical isolates and are mediated through inhibition of the penicillin-binding proteins (PBPs) PBP1 and PBP3, with very low frequency of resistance; the rarepbp3mutants with high levels of resistance to sulbactam are attenuated in fitness. These results support further investigation of the potential clinical utility of sulbactam.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
168 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献